Alquest Announced as MedNet Solutions' First iMedNet CRO Partner
MedNet Solutions and Alquest LLC, a CRO specializing in medical devices, in vitro diagnostics (IVDs), biologics, and combination products, are pleased to jointly announce that Alquest has become the first organization to join the iMedNet CRO Partner Program. Introduced last month by MedNet Solutions, the iMedNet CRO Partner Program aims to help Clinical Research Organizations (CROs) improve research efficiency, expand their service offerings, decrease internal costs, and win more business.
"We're delighted to be the first iMedNet CRO Partner with MedNet Solutions," stated Linda Alexander, Chief Executive Officer of Alquest. "Their new iMedNet EDC solution builds on the success of their proven ENLIGHTEN® software and brings eClinical capabilities to a whole new level. I'm excited to show this to our clients and provide them with this state-of-the-art solution."
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
